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Control of cutaneous leishmaniasis (CL) in the Americas is dependent on chemotherapy 
with parenteral pentavalent antimonials. High rates of treatment failure urge the search 
for predictive and prognostic markers of therapeutic responsiveness. In this study, we 
aimed to identify biomarkers of therapeutic response during treatment with meglumine 
antimoniate (MA). We conducted untargeted metabolomic profiling of plasma samples 
from CL patients (n = 39; 25 who cured and 14 who did not cure), obtained before 
and at the end of treatment. Exposure to MA induced metabolic perturbations primarily 
reflecting alteration in long-chain fatty acid β-oxidation and energy production. Allantoin, 
N-acetylglutamine, taurine, and pyruvate were significantly more abundant in samples 
from patients who responded to treatment, and were predictive and prognostic of 
treatment outcome in this patient cohort (AUC > 0.7). In an ex vivo model of infection, 
allantoin but not taurine enhanced the MA-dependent killing of intracellular Leishmania 
(Viannia) panamensis. Our results support the participation of metabolites mediating 
antioxidant and wound healing responses in clinical cure of CL, revealing relationships 
between metabolism and immune responses in the outcome of antileishmanial treatment.
Keywords: cutaneous leishmaniasis, meglumine antimoniate, pharmacometabolomics, biomarkers, allantoin, 
taurine
INTRODUCTION
Cutaneous leishmaniasis (CL) is endemic in more than 90 countries and 1 million new cases are 
estimated to be globally reported each year. Control of CL in the Americas is contingent upon 
active case detection and treatment. Although pentavalent antimonials (SbV) remain the first-line 
treatment option, therapeutic failure rates of 19% to 75% challenge its usefulness (Palacios et al., 
2001; Vélez et al., 2010). Adverse drug reactions (ADRs) have been reported to occur in up to 64% 
of individuals treated with these drugs (Oliveira et al., 2011), and can result in acute pancreatitis, 
hepatotoxicity, and death in most severe cases (Oliveira et al., 2011). The high rates of treatment 
failure and of ADR urge the identification of readily accessible and objectively measured biomarkers 
of therapeutic response and toxicity.
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Populations most affected by CL in the Americas are 
inhabitants of rural dispersed communities with limited 
access to health care systems. The extended time for patient 
follow-up required to determine the therapeutic response (3 
to 6 months) (Olliaro et al., 2013) constrains clinical follow-up 
and pharmacovigilance strategies. Identification of prognostic 
biomarkers for early definition of the therapeutic response could 
contribute to mitigate these limitations.
Pharmacometabolomic approaches have contributed to 
understanding the mechanism of action of drugs through 
identification of metabolic signatures associated with therapeutic 
responses (Johnson et al., 2012). Although scantly applied 
in neglected tropical diseases research, metabolomics has 
been recently used to explore the mechanisms of antimonial 
drug resistance in in vitro cultures of Leishmania donovani 
and Leishmania infantum; polyamides and trypanothione 
biosynthetic pathways were identified as contributors to the 
resistance phenotype (Canuto et al., 2012; Rojo et al., 2015), 
concurring with previous findings at the genome and proteome 
levels (Ouellette et al., 2004).
The feasibility of obtaining human samples for metabolomics 
such as serum, plasma, saliva, or urine, and the lower complexity 
of data matrices resulting from the smaller dimension of the 
metabolome compared with the genome (from ~30,000 genes 
to ~2,500 metabolites) strongly support its application in the 
pipeline of biomarker discovery (Johnson et al., 2016). The use 
of metabolomics toward therapeutics for neglected infectious 
diseases, such as leishmaniasis, has been underexploited. 
Only recently, Vincent et al. (2016) have documented the 
implementation of a liquid chromatography mass spectrometry 
(LC-MS) metabolic approach to identified biomarkers for 
diagnosis and definition of disease stage in human African 
trypanosomiasis. In this study we implemented an unbiased 
exploratory metabolomics approach to identify predictive and 
prognostic candidate biomarkers of the outcome of treatment 
with meglumine antimoniate (MA) in samples from patients with 
CL caused by L. Viannia, as well as to describe the metabolomic 
perturbations associated to drug exposure.
MATERIALS AND METHODS
Ethics Statement
This study was approved and monitored by the Institutional 
Review Board for Ethical Conduct of Research Involving Human 
Subjects of CIDEIM (approval code CIEIH 1209), in accordance 
with national and international guidelines for conduct of clinical 
studies. All individuals voluntarily participated in the study; each 
participant signed the informed written consent at recruitment.
Study Design and Participants
This metabolomics study was designed as a biomarker discovery 
study, aimed to determine the metabolic perturbations associated 
with exposure to antimonial drugs in CL patients, and to identify 
candidate biomarkers of antimonial treatment outcome in plasma 
samples (Figure 1). Parasitologically diagnosed CL patients (n = 
39), 18 to 47 years of age, with time of lesion evolution <6 months 
and who had a reported overall adherence to treatment with 
MA > 85% were included between years 2012 to 2015 (Table 1). 
Peripheral blood samples were taken before initiation of treatment 
and at the end of treatment from all participants. Healthy and non-
treated controls were not included as the purpose of this study was 
to identify biomarkers of therapeutic responsiveness in infected 
patients and not biomarkers of infection. Sample size could not 
be calculated as no prior data was available for probabilistic 
estimations. Therefore, sample size for our discovery study was 
defined based on the well-established biomarker pipeline and 
respective sample dimensions: discovery studies (unbiased 
semiquantitative studies of small sample size—within the tens 
of samples), qualification studies (target-driven quantitative 
small sample size studies—tens of samples), verification studies 
(targeted quantitative studies with larger cohorts, usually within 
the hundreds of samples), and validation studies (cohort studies 
within the thousands of samples) (Rifai et al., 2006).
Patients received standard-of-care treatment with MA (20 
mg/kg/day for 20 days) and clinical evaluations were conducted 
at the end of treatment and 13 weeks after initiation of treatment, 
time at which clinical outcome was determined. Peripheral 
blood samples for isolation of plasma were obtained before 
initiation of treatment and within 8 days after end of treatment. 
The clinical outcome was defined according to the most recent 
harmonization guidelines for CL (Olliaro et al., 2013, Olliaro 
et  al., 2018). Cure was defined as complete reepithelialization 
and absence of inflammatory signs for all lesions. Treatment 
failure was defined as incomplete reepithelialization and/or 
presence of induration, raised borders, or other evidence of 
inflammation of any CL lesion at the end of follow-up (90 days 
after initiation of treatment); or reactivation of the original 
FIGURE 1 | Flowchart of the study design.
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lesion(s); or  appearance of new lesions during follow-up. Safety 
monitoring was performed and recorded during the follow-up 
visits. Adverse events (AE), were recorded and standardized (by 
name and severity) according to the Common Toxicity Criteria 
of the National Cancer Institute, V 4.0 (National Cancer Institute, 
2009). Causality was established using WHO-UMC criteria and 
the Naranjo algorithm (Naranjo et al., 1981) and were reported 
as possibly, probably, or definitely related to treatment with 
MA (Table 1), and thus considered ADRs. Quality control of 
clinical data included double data entry from paper case report 
forms (CRF) to a Microsoft Office Access database, external data 
monitoring, and resolution of discrepancies by consensus.
Sample Processing and Metabolite 
Extraction
Plasma was obtained from heparin anticoagulated peripheral 
blood samples by centrifugation at 800 × g for 10  min. For 
metabolite extraction we adapted the protocol described by 
Vincent et al. (2012), and all samples were processed in a single 
batch by the same person in the same day. Briefly, 100 μl of 
plasma was mixed with chloroform/methanol (in a 1:3 ratio), 
vortexed on a cooled (4°C) mixer for 1 h, centrifuged for 10 min 
at 14,000 × g at 4°C, and the supernatant transferred and stored 
at −80°C.
LC/MS Data Acquisition and Processing
Samples were analyzed by hydrophilic interaction LC/MS (UltiMate 
3000 RSLC, Thermo Fisher) using a 150 × 4.6  mm ZIC-pHILIC 
column (Merck SeQuant) running at 300 µl/min and Orbitrap 
Exactive (Thermo Fisher) detection. Mass spectrometer parameters 
were 50,000 resolving power in positive/negative switching mode. 
Electrospray ionization (ESI) voltage was 4.5 kV in positive and 
3 kV in negative modes. Buffers consisted of (A) 20 mM ammonium 
carbonate (Sigma) in H2O and (B) Merck SeQuant: acetonitrile 
TABLE 1 | Clinical and demographic characteristics of study participants.
Characteristic Total Responders Nonresponders p value*
Number of participants 39 (100) 25 (64) 14 (36) –
Sex, n (%)
 Male 36 (92) 25 (100) 11 (78.6) 0.039‡
 Female 3 (8) – 3 (21.4)
Age in years, median (range) 30 (18–47) 30 (18–45) 29.5 (19–47) 0.735§
Ethnicity, n (%)
 African descent 37 (95) 25 (100) 12 (85.7) 0.122‡
 Other 2 (5) – 2 (1.3)
Weight, mean (SD), kg 69.4 (8.4) 67.6 (7.4) 72.4 (9.6) 0.092§
Time of disease evolution (months), 
median (range)
1 (1–5) 2 (1–5) 1 (1–5) 0.311§
Number of lesions per patient, 
median (range)
2 (1–6) 1 (1–5) 2 (1–6) 0.634§
Percentage of treatment adherence, 
median (range)†
100
(85–100)
100
(98–100)
100
(85–100)
0.075‡
Geographical area of reported infection 
(Department). n (%)
 Nariño 32 (82.1) 20 (80) 12 (85.7) 0.655‡
 Other 7 (17.9) 5 (20) 2 (14.3)
Isolated Leishmania species, n(%)
 L. V. panamensis 31 (79.5) 19 (76) 12 (85.7) 0.813‡
 L. V. braziliensis 2 (5.1) 2 (8) 0
 Not available or contaminated 6 (15.4) 4 (16) 2 (14.3)
Adverse Drug Reactions (ADR)
Patients reporting adverse drug 
reactions, n (%)
 None 12 (30.8) 6 (24) 6 (42.9) 0.286‡
 At least one 27 (69.2) 19 (76) 8 (57.1)
Intensity of ADR, n (%)
 Mild 24 (89) 17 (89) 7 (87) 1.000‡
 Moderate 3 (11) 2 (11) 1 (13)
Type of reaction, n (%)      
 Fever 18 (26.1) 12 (29.3) 6 (21.4) 0.480‡
 Pain at the injection site 9 (13.0) 3 (7.3) 6 (21.4)
 Headache 9 (13.0) 7 (17.1) 2 (7.1)
 Arthralgia 9 (13.0) 5 (12.1) 4 (14.3)
 Fatigue 5 (7.2) 3 (7.2) 2 (7.1)
 Myalgia 5 (7.2) 4 (9.8) 1 (3.6)
 Others 14 (20.3) 7 (17.1) 7 (25.0)
*Contrast between responders and non-responders. †Based on ampules received vs. ampules ordered. ‡Chi2/Fisher. §T-test/Wilcoxon rank sum test.
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(Rathburn Chemicals). The gradient ran from 20% A: 80% B to 80% 
A: 20% B in 15 min, followed by a wash at 95% A: 5% B for 3 min, 
and equilibration at 20% A: 80% B for 5 min.
Raw mass spectrometry data were processed using XCMS 
(Smith et al., 2006), MzMatch (Scheltema et al., 2011), and 
in-house R-scripts for deep filtering, post-processing, and 
identification. Peaks were visualized using PeakML Viewer 
(Scheltema et al., 2011). The data were compiled using the 
IDEOM software (Creek et al., 2012). Classification of metabolite 
annotations followed the MSI guidelines (Sumner et al., 2007). 
Compounds annotated on the basis of a <3 ppm accurate mass 
threshold, searched against the IDEOM database, were described 
as “annotations,“ while compounds matched to an authentic 
standard with <3 ppm accurate mass error and <5% retention 
time deviation were classed as “identifications.”
Quality Control of LC/MS Data
Aliquots from each sample were pooled to generate a quality 
control (QC) master sample. All samples were analyzed in 1 
day and in one batch in a randomized manner. Stock solutions 
of 116 authentic standard compounds were prepared in ethanol, 
50% ethanol/water, or Milli-Q water, depending on solubility 
(Figure  S1). A working solution containing all authentic 
standards was prepared and run at the beginning and at the 
end of the run (Creek et al., 2011). The QC was injected before 
starting the LC/MS run and every five samples for stable run 
assurance. The quality of the chromatography and signal 
reproducibility was checked by analysis of QC samples, internal 
authentic standards, and total ion chromatograms. Samples that 
displayed unacceptable analytical variation (retention time drift) 
were removed from further analysis. Metabolites with more 
than 20% missing values, confidence identification <5, and drug 
derivatives were excluded from the analysis. Additional manual 
curation was performed on all datasets confirming identification 
and removing false identifications based on peak quality.
Data Curation and Statistical Analysis
Clinical and demographic data were analyzed using R software 
version 3.3.2 and STATA 14, using untransformed data. For 
metabolomic data, principal component analysis (PCA) analysis 
was used to identify outlier samples. MetaboAnalyst 4.0 (Chong 
et al., 2018), XCMS, and GraphPad Prism 6 were used for data 
analysis and interpretation. Peak intensity table was normalized 
by probabilistic quotient normalization (Dieterle et al., 2006), 
generalized log transformed, and Pareto scaled (van den Berg 
et al., 2006). A statistical pipeline based on univariate (Student’s 
t-test and ANOVA) and multivariate analyses [orthogonal partial 
least squares discriminant analyses (OPLS-DA)] was used to 
identify metabolites associated with drug exposure, toxicity, and 
treatment outcome. OPLS-DA statistics R2Y and Q2 represent 
the total sum of variation in Y explained by the model, and 
the goodness of prediction calculated by full cross-validation, 
respectively (Worley and Powers, 2012). KEGG, MetaboAnalyst 
4.0, and text mining were used for pathway analyses (Chong 
et al., 2018). ROC curves were constructed by logistic regression.
Cytotoxicity Assay
Cytotoxicity of candidate metabolites was evaluated in THP-1 
cells in dose response experiments: allantoin (0.005 mM–31 
mM) and turine (0.05 mM–10 mM). The range of allantoin doses 
was selected based on its maximum solubility in RPMI medium 
(≈31 mM) and FDA-approved doses for local therapy as a skin 
protectant (≈31–126 mM) (FDA, 1978). Taurine concentrations 
were based on those found in plasma in healthy individuals 
(Marcinkiewicz and Kontny, 2014) and those reported as 
cytoprotective concentrations (Eppler and Dawson, 2002). 
One hundred thousand cells were seeded in a 96-well plate in 
RPMI medium supplemented with 10% FBS and incubated at 
37°C, 5% CO2 with allantoin or taurine for 72  h. Cytotoxicity 
was evaluated using the MTT (3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide) method following the 
manufacturer’s instructions (ATCC) (Figure S2).
PBMCs Isolation, Ex Vivo Infection, 
and Parasite Survival Assays
Blood samples were collected from six CL patients before 
initiation of treatment. Peripheral blood mononuclear cells 
(PBMCs) were isolated by centrifugation over a Histopaque 1077 
gradient (Sigma-Aldrich). PBMCs were resuspended in RPMI 
with 10% FBS and seeded in 96-well plates. Cells were infected in 
a 1:10 parasite-to-monocyte ratio for 24 h with serum-opsonized 
L.V. panamensis (transfected with the luciferase reporter gene) 
as previously optimized and described (Gonzalez-Fajardo et al., 
2015). Taurine or allantoin (Sigma-Aldrich) were added alone 
or in combination (simultaneous exposure) with 4 μg/ml MA 
for 72 h at 34°C, 5% CO2, and parasite burden was evaluated by 
luminometry (Gonzalez-Fajardo et al., 2015).
RESULTS
Clinical and Demographic Characteristics 
of Study Participants
A total of 39 participants were included in this study, 25 who 
responded to MA treatment and 14 who did not respond (Table 1, 
Figure 1). The majority of participants (92%) were young adult 
males of Afro-Colombian descent from the department of 
Nariño, Colombia. No significant differences were found in 
demographic or clinical characteristics between groups, with 
the exception of gender where the only three female participants 
were recruited to the treatment failure group (p = 0.04). At least 
one ADR was found in 27 participants (69%), the most common 
ones being fever (18.4%) followed by pain at the injection site 
(9.2%) and headache (9.2%) (Table 1). No serious adverse events 
were reported.
Exposure to MA Alters the Plasma 
Metabolome of CL Patients
Based on the raw metabolite data, metabolomes from four patients 
(three responders and one of the female non-responders) were 
excluded from further analyses; two of them had poor quality 
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peak spectra, while the other two were identified as outliers in 
the PCA (Figure S3). No statistical differences in clinical and 
demographic variables were found among groups after outlier 
exclusion. After data curation and quality control, from a total 
of 11,309 features, 536 metabolites were detected in plasma 
samples and 48 metabolites were identified against authentic 
pure standards (Dataset S1). The remaining 488 metabolites 
were classified as annotated. N-methyl glucamine (meglumine), 
a by-product of MA, was detected in all post-treatment samples 
(relative mean intensity 26.734) serving as an indicator of drug 
exposure in the study population; this metabolite was excluded 
from further analysis.
The abundance of 30.4% of detected metabolites (163 of 536) 
was significantly modified after in vivo exposure to MA [paired 
t-test p ≤ 0.05, false discovery rate (FDR) ≤0.1], 19 of which were 
identified against an authentic pure standard. Fifty-three percent 
(88 of 163) were more abundant after treatment (Figure 2A and 
Dataset S2). To select metabolites that were consistently modified 
after antimonial drug exposure, data were analyzed by OPLS-DA. 
Of the 163 differentially abundant metabolites found by paired 
t-test analysis, 38 were also discriminatory by OPLS-DA (sum 
R2Y = 0.93 and cross-validation test Q2 = 0.62; cutoff thresholds 
of 1.5 ≤ p[1] ≤ -1.5 and 0.3 ≤ p (corr)[1] ≤ -0.3 in the S-plot; 
Dataset S2 and Figure S4). Among these, six metabolites were 
identified: betaine, choline phosphate, D-ribose, L-carnitine, 
S-malate, and xanthine (Figure 2B). The relative abundance of 
betaine, xanthine, and D-ribose increased after treatment, while 
S-malate, choline phosphate, and L-carnitine decreased. Both 
annotated and identified metabolites were included for metabolic 
pathway analysis, showing that metabolites within the pathways 
of long-chain fatty acid metabolism and β-oxidation (L-carnitine 
and choline phosphate, 3-methylglutarylcarnitine, and cis-5-
tetradecenoylcarnitine), redox balance (choline phosphate, 
guanidinoacetate, S-malate, L-dehydroascorbate, and betaine), 
and nucleotide metabolism (S-dihydroorotate, 3-methylguanine, 
D-ribose and xanthine) were significantly and differentially 
abundant after MA exposure (Dataset S2).
Metabolites Associated With Wound 
Healing and Redox Balance Are 
Differentially Abundant in Responders 
and Non-Responders
An OPLS-DA model was constructed to select metabolites that 
could discriminate between patients that cured (responders, n = 
22) and patients that did not cure (non-responders, n = 13). Pre-
treatment and end-of-treatment plasma samples were included 
for this analysis. The model allowed separation of samples from 
responders and non-responders with a sum R2Y: 0.96 and cross-
validation test Q2: 0.55 (Figure 3A). Cutoff thresholds of 0.65 ≤ 
p[1] ≤ -0.65 and 0.3 ≤ p (corr)[1] ≤ -0.3 in the S-plot were defined 
for selection of the most discriminatory metabolites. Of 30 
metabolites with discriminatory potential, 26 were annotated and 
4 were identified against an authentic pure standard (Dataset S3).
FIGURE 2 | Exposure to meglumine antimoniate alters the plasma metabolome of CL patients. Plasma samples from CL patients (n = 35) obtained before (Pre) 
and at the end of treatment (Post) with MA were analyzed by LC/MS. (A) Heatmap representation of the normalized relative intensity of metabolites with significantly 
different abundance between samples obtained before and at the end of treatment, built using Euclidean distance and ward clustering algorithm. (B) Paired dot plot 
of identified metabolites significantly modulated after treatment with MA. Data were normalized using the pooled sample from the pre-treatment group. Statistical 
significance in dot plots was determined using paired t-test. *p <0.0.
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A four-way ANOVA with Fisher´s LSD post hoc analysis 
was conducted to strengthen selection of candidate metabolites 
predictive and prognostic of the therapeutic response (Dataset 
S3). In this analysis, 30 metabolites could discriminate responders 
from non-responders, 4 of these exclusively in pre-treatment 
samples (p ≤ 0.05, FDR ≤ 0.1), 11 exclusively in post-treatment 
samples, and 15 in both pre- and post-treatment plasma samples 
(Dataset S3). Seventeen differentially abundant metabolites were 
also found as discriminatory by OPLS-DA. Of these, 13 were 
annotated and 4 identified (Table 2).
Of the annotated metabolites, six were related to lipid 
metabolism (two fatty acyls, taurochenodeoxy-cholate-3-
sulfate, glycochenodeoxycholate 7-sulfate, sterol lipids, and 
stearoylcarnitine), two with energy metabolism (D-erythrose 
and ethylpyruvate), and five with amino acid metabolism 
(N5-ethyl-L-glutamine, N6-methyl-L-lysine, 2 hydroxypyridine, 
Glu-Phe-Trp, and Ala-Lys-Ser-Arg) (Table 2). All identified 
metabolites (taurine, N-acetylglutamine, allantoin, and pyruvate) 
participate in antioxidant and wound healing responses, and 
were consistently found more abundant in responders both in 
pre- and post-treatment samples (Figure 3B). Among identified 
metabolites, the abundance of taurine and allantoin significantly 
increased at the end of treatment in patients who responded to 
treatment, in contrast to non-responders (Figure 3B). Allantoin, 
N-acetylglutamine, taurine, and pyruvate had both predictive 
and prognostic potential as determined by ROC curves of data 
from pre-treatment and post-treatment samples, respectively 
(AUC >0.7) (Figure 4). ROC curve analyses of the individual 
metabolites or a composite metabolic signature including 
allantoin, N-acetylglutamine, taurine, and pyruvate showed that 
taurine had the highest predictive and prognostic potential in 
our patient cohort (AUC = 0.75 and AUC = 0.82, respectively) 
(Figure 4).
Allantoin Promotes MA-Dependent Killing 
of L.V. Panamensis
Allantoin and taurine have been described as important 
mediators of wound healing and participate in antioxidant 
responses (Araújo et al., 2010; Eppler and Dawson, 2002; 
Macalister, 1912). Based on this, we explored whether these 
metabolites could enhance the antimony-mediated killing of 
Leishmania. PBMCs from CL patients were infected ex vivo 
with L. V. panamensis and exposed to 10 mM taurine or 10 mM 
allantoin alone or in combination with MA. Selection of these 
doses was based on concentrations not cytotoxic for cells, and in 
the case of allantoin we also consider the minimum dose allowed 
by FDA for use as a topical treatment and its solubility in RPMI 
medium. Exposure to taurine or allantion alone, or taurine in 
combination with MA, did not modify the parasite burden of 
infected PBMCs. However, when infected cells were exposed to 
allantoin in combination with MA (4 µg/mL), parasite killing 
was significantly enhanced compared to the MA-only control 
(Figure  5), indicating a potential contribution of allantoin in 
antimony-mediated parasite killing.
DISCUSSION
Despite the high rates of treatment failure and ADRs, systemic 
pentavalent antimonials remain the first-line treatment for CL. 
Unnecessary exposure of patients to these highly toxic drugs 
should be minimized, and thus identification of predictive 
biomarkers of treatment outcome is a priority in the clinical 
management of CL. Assessment of therapeutic response 
FIGURE 3 | Metabolites associated with wound healing and redox balance 
are more abundant in CL patients who cured. (A) OPLS-DA model of 
metabolites depicts the separation of all samples (pre- and post-treatment) 
in each group (responders and non-responders), each circle representing an 
individual sample. (B) Scatter dot plots of selected metabolites differentially 
abundant between responders and non-responders. Whiskers represent 
the 5–95 percentile. Data were normalized using the pooled sample from 
plasmas of the responders group. Statistical significance was determined 
using t-test. *p <0.05.
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for CL is conducted at 3 and 6 months after initiation of 
treatment. However, the occurrence of CL in dispersed rural 
settings constrains access to treatment, treatment follow-up, 
and pharmacovigilance actions. Thus, early predictors of the 
therapeutic response (predictive and prognostic biomarkers) 
could support public health interventions and clinical 
practice. In this study, we provide the first metabolomic 
profiles of CL patients undergoing treatment with pentavalent 
antimonials, and report a set of predictive and prognostic 
candidate biomarkers of therapeutic outcome to be scaled 
toward biomarker validation studies. Increased levels of 
allantoin, taurine, and N-acetylglutamine, metabolites 
involved in antioxidant and wound healing responses, were 
detected before and at the end of treatment in patients who 
cured. This supports the fact that induction of host immune/
wound healing responses during treatment, in addition to 
controlling the parasite burden,  is central to therapeutic 
cure, and furthermore highlights a previously unrecognized 
participation of antioxidant mechanisms in healing of CL.
Exposure to metalloids such as antimony results in 
disturbance of ATP production, induction of oxidative 
and osmotic stress (in part due to production of reactive 
oxygen species), lipid peroxidation, and downstream loss of 
membrane integrity (Gebel, 1997; Pulido, 2003; Wyllie and 
Fairlamb, 2006; Bento et al., 2013). Drug-induced perturbation 
of metabolites associated with redox balance is reflected by 
the significant increase in betaine, D-ribose, and xanthine 
and decrease of choline phosphate and S-malate at the end 
of treatment. Betaine protects against osmotic stress (Obeid, 
2013) and redox imbalances primarily through homocysteine 
conversion to methionine (Ganesan et al., 2011). Reduced 
abundance of choline phosphate is consistent with its oxidation 
to betaine and with the higher levels of betaine found after 
treatment with MA. D-ribose and xanthine are metabolites 
within purine biosynthetic pathways. Their higher abundance 
after drug treatment could contribute to protection against 
metal-induced oxidative stress through the oxidative branch 
of the pentose phosphate pathway by production of NADPH 
and purine degradation to urate, the major antioxidant in the 
blood (Patra and Hay, 2014). These results provide evidence 
that the plasma metabolome of CL patients exposed to MA 
reflects a response against the oxidative stress induced by 
antimonial drugs.
The mechanisms of action of antimonials are not fully 
understood (Croft et al., 2006; Gebel, 1997; Oliveira et al., 
2011). It has been shown that exposure to antimonials leads 
to inhibition of fatty acid β-oxidation, and this has been 
considered part of the mechanism(s) of antileishmanial 
action (Berman et  al., 1987; Croft et al., 2006). However, how 
these drugs modulate fatty acid β-oxidation is still unknown. 
Our results showed that L-carnitine, a facilitator of fatty 
acid transport to the mitochondria for β-oxidation (Vaz and 
Wanders, 2002), was less abundant at the end of treatment in 
CL patients, compared to pre-treatment samples. Concordantly, 
other acylcarnitine intermediates (3-methylglutarylcarnitine 
and cis-5-tetradecenoylcarnitine) associated with dysfunction 
of normal fatty acid β-oxidation (Roe et al., 1986; Wood 
et  al., 2001; Vaz and Wanders, 2002; Rinaldo et al., 2008) 
were increased after MA  treatment. These  results suggest  that 
reduced lipid transport to the mitochondria could contribute 
TABLE 2 | Plasma metabolites with significant differences in CL patients that responded or did not respond to MA treatment.
Metabolites‡ Elemental formula Mass (Da) RT (min) p value FDR Post hoc Fisher’s 
LSD* 
Taurine§ C2H7NO3S 125.01 13.55 0.00028 0.00948 1-2; 3-4
Allantoin§ C4H6N4O3 158.04 13.28 0.00324 0.05261 1-2; 3-4
N-acetylglutamine§ C7H12N2O4 188.08 10.57 0.00805 0.09197 1-2; 3-4
Pyruvate§ C3H4O3 88.016 7.93 0.01005 0.09606 1-2; 3-4
D-erythrose C4H8O4 120.04 10.34 0.00012 0.00600 1-2; 3-4
Taurochenodeoxycholate-
3-sulfate
C26H45NO9S2 289.63 4.34 0.00017 0.00723 1-2; 3-4
Ala-Lys-Ser-Arg C18H36N8O6 230.14 13.27 0.00019 0.00743 1-2; 3-4
Glycochenodeoxycholate 
7-sulfate
C26H43NO8S 264.64 4.66 0.00038 0.01079 3-4
2-Hydroxypyridine C5H5NO 95.04 7.98 0.00076 0.01951 1-2; 3-4
FA methyl jasmonate C13H20O3 224.14 3.94 0.00162 0.03192 1-2; 3-4
N6-methyl-L-lysine C7H16N2O2 160.12 19.26 0.00427 0.06468 1-2; 3-4
ethylpyruvate C5H8O3 116.05 5.34 0.00435 0.06468 1-2; 3-4
Fatty acyls¶ C13H18O5 254.12 5.25 0.00459 0.06650 1-2; 3-4
Glu-Phe-Trp C25H28N4O6 240.1 7.71 0.00558 0.07844 1-2; 3-4
Sterol lipids|| C24H40O4 392.29 4.83 0.00855 0.09197 1-2
N5-ethyl-L-glutamine C7H14N2O3 174.1 12.66 0.00900 0.09197 1-2; 3-4
Stearoylcarnitine C25H49NO4 427.37 4.72 0.00945 0.09197 3-4
‡Data was normalized using a pooled sample from responders, gLog2 transformed and pareto scaled. RT: retention time in minutes, mass in Daltons.
*Group contrasts with statistical significance in the Fisher LSD post hoc: 1: responders pre-treatment, 2: non-responders pre-treatment, 3: responders post-treatment, 4: 
non-responders post-treatment.
§In bold, metabolites identified against an authentic pure standard.
¶[FA methyl_hydroxyl_oxo(5:2/4:0)] methyl 4-[2-(2-formyl-vinyl)-3-hydroxy-5-oxo-cyclopentyl]-butanoate.
||[ST hydrox] 3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid.
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to the MA-induced perturbations in fatty acid β-oxidation or 
metabolic adaptations to the stressor. Although these inferences 
derive from observations of human plasma samples and reflect 
the functions of host cells, these same mechanisms could also 
be operating in Leishmania cells; however, this remains to be 
demonstrated.
In our study, plasma metabolites involved in inflammatory 
and oxidative stress pathways were identified as candidate 
biomarkers of the outcome of treatment. ROC curve analyses 
showed that taurine, allantoin, pyruvate, and N-acetylglutamine 
had the potential to be both predictive and prognostic biomarkers 
in our patient cohort. N-acetylglutamine, allantoin, and taurine 
have important roles in the control of oxidative stress, regulation 
of inflammatory responses (Magnusson et al., 1989; Gürer et al., 
2001; Marcinkiewicz and Kontny, 2014; Altman et al., 2016), and 
in wound healing (Macalister, 1912; Eppler and Dawson, 2002; 
Araújo et al., 2010). Both the immune response and exposure to 
MA generate a strong oxidative environment within the human 
host. In this context, the first host response to this oxidizing 
environment is to increase antioxidant defense mechanisms. We 
speculate that increased antioxidant capacity in patients who 
respond to treatment, portrayed by higher levels of allantoin, 
taurin, and N-acetylglutamine, reflects higher oxidative stress, 
which in turn, could contribute to enhanced drug and ROS-
mediated parasite killing, favoring therapeutic cure.
Allantoin, a downstream product of purine degradation, 
has been used as skin protectant in dermatological conditions 
(Government, U.S., 2010; Macalister, 1912; Madrazo-Jimenez 
et al., 2016). The oxidative stress induced upon exposure to MA 
could result in production of allantoin from purine degradation 
and urate interconversion. Higher abundance of taurine and 
allantoin in CL patients who cured, together with the evidence that 
allantoin promotes antimony-mediated parasite killing, concurs 
with their biological role as skin protectants and enhancers of 
wound healing, suggesting that in addition to serving as putative 
biomarkers of outcome, these metabolites could also contribute to 
drug-induced healing of CL through host-targeted mechanisms.
Leishmaniasis has been historically more frequently 
reported in adult males, primarily due to occupational exposure 
(Uribe-Restrepo et al., 2019). This contributes to one of the 
limitations of this study, which was the minimal inclusion of 
women for metabolomic profiling and the absence of children 
samples in the analyses. Considering the discovery nature of 
our study design, the target population was controlled as much 
as possible in terms of age, sex, ethnicity, and geographical 
region of origin to reduce demographic variability that could 
influence the metabolic profiles and that could skew candidate 
FIGURE 4 | Metabolites with predictive and prognostic potential of treatment 
outcome. ROC curves represent the area under the curve (AUC) of the 
false-positive rate vs. the true positive rate. Data from all samples for each 
individual metabolite, or the combination of the four selected metabolites 
(ALL), were used to construct the ROC curves. ROC curves of metabolites 
identified in pre-treatment samples are shown in the left and in post-treatment 
samples in the right. CI: confidence interval.
FIGURE 5 | Allantoin potentiates antimony-mediated killing of intracellular 
Leishmania. Peripheral blood mononuclear cells from six CL patients were 
infected ex vivo with L. V. panamensis (L.p.) for 24 h. Taurine (10 mM) or 
allantoin (10 mM) was added alone or in combination with MA (4 μg/ml) 
for 72 h, and parasite burden was evaluated by luminometry. Shown is the 
percent parasite survival relative to infected and untreated cells. Statistical 
significance was determined by t-test. *p < 0.05.
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biomarkers selection. This limitation should be addressed in 
future validation studies using targeted metabolomics in larger 
patient cohorts that are age and sex matched, where the current 
data will serve as the basis for probabilistic estimation of the 
sample size.
Metabolic profiling of samples obtained by techniques of 
minimal invasiveness, such as collection of serum/plasma, 
urine, or saliva, facilitates the identification of biomarkers with 
a high potential to be translatable to the clinic. Implementation 
of metabolomics in neglected infectious disease research is just 
emerging, and most exploratory studies have been conducted in 
the context of African and American trypanosomiasis (Requena-
Méndez et al., 2013; Vincent et al., 2016). Our discovery study 
reports the first plasma metabolomes of CL patients undergoing 
treatment with first-line MA, and provides the knowledge 
base for follow-up studies by establishing a set of candidate 
biomarkers to move forward to the validation, verification, and 
qualification phases of the pipeline of biomarkers of therapeutic 
responsiveness in CL.
Results presented here highlight the participation of 
metabolites mediating antioxidant and wound healing 
responses in clinical cure of CL, paving the way for the 
unexplored field of immunometabolomics, as a tool to inform 
novel therapeutics for leishmaniasis. Combination therapies of 
antileishmanial drugs and immunomodulators constitute one 
of the main approaches for novel antileishmanial therapies, 
seeking to reduce parasite burden while restoring immune 
homeostasis. A combination therapy of antimony and topical 
allantoin will constitute a next study phase, aiming to optimize 
antileishmanial treatment by reducing the exposure to toxic 
antimony doses, while promoting a healing response. Together, 
these results provide the research community with a set of 
well-defined candidate biomarkers for future validation, and 
constitute an important step toward urgently needed, clinically 
implementable methods to provide personalized medicine 
approaches for CL treatment.
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